BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 31362850)

  • 1. Defining and Modulating 'BRCAness'.
    Byrum AK; Vindigni A; Mosammaparast N
    Trends Cell Biol; 2019 Sep; 29(9):740-751. PubMed ID: 31362850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA repair and cell cycle checkpoint defects in a mouse model of 'BRCAness' are partially rescued by 53BP1 deletion.
    Misenko SM; Patel DS; Her J; Bunting SF
    Cell Cycle; 2018; 17(7):881-891. PubMed ID: 29620483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality.
    Murai J; Pommier Y
    Cancer Res; 2023 Apr; 83(8):1173-1174. PubMed ID: 37057596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
    Stok C; Kok YP; van den Tempel N; van Vugt MATM
    Nucleic Acids Res; 2021 May; 49(8):4239-4257. PubMed ID: 33744950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.
    Abbotts R; Topper MJ; Biondi C; Fontaine D; Goswami R; Stojanovic L; Choi EY; McLaughlin L; Kogan AA; Xia L; Lapidus R; Mahmood J; Baylin SB; Rassool FV
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22609-22618. PubMed ID: 31591209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARPi focus the spotlight on replication fork protection in cancer.
    Schlacher K
    Nat Cell Biol; 2017 Oct; 19(11):1309-1310. PubMed ID: 29087384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploiting replication gaps for cancer therapy.
    Cong K; Cantor SB
    Mol Cell; 2022 Jul; 82(13):2363-2369. PubMed ID: 35568026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
    Murai J
    Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
    Haynes B; Murai J; Lee JM
    Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic exploitation of tumor cell defects in homologous recombination.
    Powell SN; Kachnic LA
    Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer.
    Hu Y; Guo M
    Cancer Sci; 2020 Sep; 111(9):3111-3121. PubMed ID: 32639661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Mechanism to Induce BRCAness in Cancer Cells.
    Cai C
    Cancer Res; 2020 Jul; 80(14):2977-2978. PubMed ID: 32669350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.
    Lim D; Ngeow J
    Endocr Relat Cancer; 2016 Jun; 23(6):R267-85. PubMed ID: 27226207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCAness revisited.
    Lord CJ; Ashworth A
    Nat Rev Cancer; 2016 Feb; 16(2):110-20. PubMed ID: 26775620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.
    Chalasani P; Livingston R
    Oncologist; 2013; 18(8):909-16. PubMed ID: 23881989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
    Ning J; Wakimoto H
    Trends Cancer; 2020 Feb; 6(2):147-159. PubMed ID: 32061304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.